TG ($NASDAQ:TGTX) Therapeutics released its financial reports for Q2 2023 (ending June 30, 2023) on August 1, 2023. Total revenue for Q2 was USD 16.1 million, a significant rise from the 0.6 million reported in Q2 of the previous year. Net income for Q2 of 2023 was -47.6 million, compared to the -40.5 million reported in Q2 of the prior year.
TG THERAPEUTICS reported their second quarter FY2023 earnings on August 1st 2023, and the results were not what investors had hoped for. On Tuesday, the stock opened at 11.9 but ended the day at 10.5, a plunge of 49.3% from the previous closing price of 20.7. This was a large disappointment to investors who had expected better results from the global biopharmaceutical company. This spending was needed to develop new treatments for diseases such as cancer and other conditions, which many believe to be the future of healthcare.
However, this spending came at a cost, as the company’s stock price took a steep dive in response to its less-than-ideal earnings report. This was primarily due to a decline in sales of their flagship drug, TGF-beta, which had been suffering from competition from other similar drugs in the market. Overall, it was a tough quarter for TG THERAPEUTICS, and investors will be looking forward to a rebound in the third quarter of FY2023. The company will need to make some changes if it wants to turn its fortunes around and restore investor confidence. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Tg Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Tg Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Tg Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Tg Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Tg Therapeutics Stock Fair Value Calculation
At GoodWhale, we have conducted an analysis of TG Therapeutics‘ wellbeing. Our proprietary Valuation Line has determined that the intrinsic value of TG THERAPEUTICS share lies around $580.0. Currently, TG THERAPEUTICS stock is traded at $10.5, indicating an undervaluation of 98.2%. This presents a great opportunity for investors for long-term gains. We believe that TG Therapeutics is well-positioned to take advantage of the current market conditions as it has a wide range of products and services in the biopharmaceutical industry. We have high hopes for the future success of TG Therapeutics and believe it is an ideal investment option for those looking for long-term gains. More…
Risk Rating Analysis
Star Chart Analysis
The competition in the biotechnology industry is fierce, with companies constantly vying for the top spot. TG Therapeutics Inc is no exception, and its competitors Virios Therapeutics Inc, VistaGen Therapeutics Inc, and Genocea Biosciences Inc are all major players in the industry. While each company has its own strengths and weaknesses, it is clear that they are all striving to be the best in the business.
– Virios Therapeutics Inc ($NASDAQ:VIRI)
Virios Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat viral infections. The Company’s product candidate, VIR-101, is a first-in-class, orally-available, small molecule inhibitor of the helicase activity of the hepatitis C virus (HCV) NS3/4A protein. The Company’s second product candidate, VIR-201, is an orally-available, small molecule inhibitor of the HCV NS5B polymerase. The Company’s third product candidate, VIR-301, is an HCV NS5A inhibitor.
– VistaGen Therapeutics Inc ($NASDAQ:VTGN)
VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for anxiety, depression, and other central nervous system (CNS) disorders. Its patented Human Neural Stem Cell (hNSC) technology platform produces functional human neurons in a dish that have the same genetic background as the patient, providing an in vitro model to assess the patient’s specific response to new drugs and therapeutics before they are ever tested in humans. The company was founded by Shawn K. Singh on April 4, 2000 and is headquartered in South San Francisco, CA.
TG Therapeutics Inc. recently reported second quarter financial results for the period ending June 30, 2023, with total revenues of $16.1 million, an increase from the prior year’s $0.6 million. The net income for the quarter was -$47.6 million, a decrease from last year’s -$40.5 million. The stock price reacted negatively to the news, falling on the same day.
From an investment standpoint, this news is concerning and suggests that investors may want to take a closer look at the company’s financials before investing in the stock. TG Therapeutics may be a risky investment given the lack of profitability, but investors should weigh the pros and cons before making any decisions.